The pharmaceutical sector in India continues to gain momentum, with top companies announcing strong quarterly results. Are you tracking some of the best-performing stocks in this segment?
With consistent growth in exports, strong domestic demand, and a focus on specialty drugs, pharma stocks are a popular pick for long-term investors. In the last few quarters, several companies have undergone strategic developments, from drug approvals to dividend announcements.
In this blog, we have curated five key pharmaceutical stocks that investors should watch out for this quarter.
5 Good Pharmaceutical Stocks Investors Have on Their Radar
Considering recent quarterly results and the potential for an uptrend, here are five promising pharmaceuticals stocks to track.
1. Sun Pharmaceutical Industries
In terms of market capitalization, Sun Pharma is the largest pharma company in India. It’s a global leader in generics and specialty formulations, serving over 100 countries. Sun Pharma has a strong presence in the US, India, and other emerging markets.
In Q4 FY25, the company announced a revenue of INR 12,958.8 crore, while its net profit stood at INR 2,149.8 crore. The company has also declared a dividend of INR 5.50 per share for July 2025.
Sun Pharma has strengthened its specialty drug portfolio and entered new therapeutic areas like dermatology and ophthalmology. Its consistent international revenue and strategic acquisitions are some of the factors that attract investors.
2. Dr. Reddy’s Laboratories
Dr. Reddy’s Laboratories has a strong presence in India, the US, and Russia. The company focuses on generics, APIs, and proprietary products.
In Q4 FY25, it posted a net profit of INR 1,593.9 crore and a revenue of INR 8,542 crore. It also declared a dividend of INR 8 per share for July 2025.
The strong earnings reflect healthy growth and an improved product mix. The company has also taken cost control measures, while its strong product line contributes to sustained performance.
3. Cipla
Cipla is a leading global pharmaceutical company, known for its respiratory, anti-retroviral, and oncology segments. It has a strong presence in India, South Africa, and North America.
For Q4 FY25, Cipla reported a net profit of INR 1,222 crore, while it recorded a revenue of INR 6,730 crore in the same quarter. Investors consider Cipla as one of the key uptrend stocks in the pharma industry. Its strong presence in India with innovative formulations and entry into peptide therapies gives it a competitive edge.
With a focus on chronic therapies and innovation, Cipla is well-positioned for long-term growth.
4. Zydus Lifesciences
Zydus Lifesciences is a vertically integrated healthcare company with its key strengths in generics, vaccines, biologics, and wellness products.
For Q4FY24, Zydus reported a net profit of INR 1,171 crore and revenue of INR 6,528 crore. It also announced a strong dividend payout of INR 11 per share in July 2025.
With successful product launches and expansion in the US market, the company appeals to investors with its strong growth trajectory. Also, its pipeline in biosimilars and vaccines may define its success in the long run.
5. Biocon
Biocon is a leading biopharmaceutical company specializing in biologics, biosimilars, and research services. It plays a pivotal role in the insulin and oncology segments. Net profit of the company soared to INR 344 crore in Q4FY24, while its revenue stood at INR 4,454 crore. Currently, the company continues to invest heavily in R&D and global collaborations.
The biosimilar portfolio of the company in the US and gaining momentum and partnerships with global giants like Viatris, positioning it well for scalability in the future.
Wrapping Up
As the pharma sector continues to streamline India’s exports and growth in the healthcare sector, these five companies can appeal to investors. With their leadership in innovation and market expansion, pharma companies can be a part of a diversified portfolio.
